IR@PKUHSC  > 北京大学药学院
学科主题药学
Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin alpha 3 in triple-negative breast cancer
Dai, Wenbing1; Yang, Fang1; Ma, Ling1; Fan, Yuchen1; He, Bing1; He, Qihua2; Wang, Xueqing1; Zhang, Hua2; Zhang, Qiang1
关键词Triple-negative breast cancer Liposomal doxorubicin Targeting delivery Rapamycin Combined therapy
刊名BIOMATERIALS
2014-07-01
DOI10.1016/j.biomaterials.2014.03.036
35期:20页:5347-5358
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Engineering, Biomedical ; Materials Science, Biomaterials
研究领域[WOS]Engineering ; Materials Science
关键词[WOS]INDUCIBLE FACTOR-I ; DRUG-COMBINATION ; TUMOR-CELLS ; EXPRESSION ; MDA-MB-231 ; RECEPTORS ; CARCINOMA ; APOPTOSIS ; THERAPY ; GROWTH
英文摘要

A novel therapeutic strategy combining mTOR inhibitor rapamycin (RAPA) and doxorubicin (DOX)-loaded cyclic octapeptide liposomes for targeting integrin alpha 3 was expected to combat the triple-negative breast cancer (TNBC). RAPA was loaded into PEG-PCL polymer micelles (M-RAPA) to realize solubilization. Flow cytometry analysis and laser confocal microscopy were used to evaluate the in vitro cellular uptake. The in vivo tumor targeting and bio-distribution were investigated by living fluorescence imaging. As the results, LXY modification significantly enhanced the cellular uptake of liposomal DOX in integrin alpha 3 overexpressed TNBC cells (MDA-MB-231) in vitro and accordingly improved the tumor accumulation of liposomes in vivo. When used alone or in combination with IXY-LS-DOX, M-RAPA could greatly inhibit the expression of HIF-1 alpha protein, which is always highly expressed in malignant cancers and involved in tumor angiogenesis, proliferation, therapeutic resistance and poor prognosis. Meanwhile, the improved efficacy of combined targeted therapy with LXY-LS-DOX and M-RAPA was demonstrated by the in vitro cytotoxicity against model TNBC cells and in vivo anti-tumor activity against mouse bearing TNBC model. These results suggested that the targeted combinational therapy based on LXY-LS-DOX and M-RAPA systems may provide a rational strategy to improve therapeutic outcomes of TNBC. (c) 2014 Elsevier Ltd. All rights reserved.

语种英语
WOS记录号WOS:000336471300008
项目编号81130059 ; 2009CB930300
资助机构National Natural Science Foundation of China ; National Basic Research Program of China
引用统计
被引频次:24[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/62331
专题北京大学药学院
北京大学医学部管理机构_医学部
北京大学基础医学院
北京大学药学院_药剂学系
作者单位1.Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing 100191, Peoples R China
2.Peking Univ, Med & Hlth Analyt Ctr, Beijing 100191, Peoples R China
推荐引用方式
GB/T 7714
Dai, Wenbing,Yang, Fang,Ma, Ling,et al. Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin alpha 3 in triple-negative breast cancer[J]. BIOMATERIALS,2014,35(20):5347-5358.
APA Dai, Wenbing.,Yang, Fang.,Ma, Ling.,Fan, Yuchen.,He, Bing.,...&Zhang, Qiang.(2014).Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin alpha 3 in triple-negative breast cancer.BIOMATERIALS,35(20),5347-5358.
MLA Dai, Wenbing,et al."Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin alpha 3 in triple-negative breast cancer".BIOMATERIALS 35.20(2014):5347-5358.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Dai, Wenbing]的文章
[Yang, Fang]的文章
[Ma, Ling]的文章
百度学术
百度学术中相似的文章
[Dai, Wenbing]的文章
[Yang, Fang]的文章
[Ma, Ling]的文章
必应学术
必应学术中相似的文章
[Dai, Wenbing]的文章
[Yang, Fang]的文章
[Ma, Ling]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。